Selexis Sa

Selexis Sa company information, Employees & Contact Information

Explore related pages

Related company profiles:

KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings.
Looking for a particular Selexis Sa employee's phone or email?

Selexis Sa Questions

News

JSR Life Sciences Acquires Selexis - CHEManager

JSR Life Sciences Acquires Selexis CHEManager

Selexis / KBI Biopharma - Massachusetts Biotechnology Council

Selexis / KBI Biopharma Massachusetts Biotechnology Council

KBI Biopharma And Selexis SA Appoints Abdelaziz Toumi, Ph.D. As Chief Business Officer - citybiz

KBI Biopharma And Selexis SA Appoints Abdelaziz Toumi, Ph.D. As Chief Business Officer citybiz

Cell Line Development: Emerging Platforms - BioProcess International

Cell Line Development: Emerging Platforms BioProcess International

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO - Business Wire

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO Business Wire

Advertorial: Selexis - Genetic Engineering and Biotechnology News

Advertorial: Selexis Genetic Engineering and Biotechnology News

KBI Biopharma and Selexis open a new biologics manufacturing facility in Geneva - Greater Geneva Bern area

KBI Biopharma and Selexis open a new biologics manufacturing facility in Geneva Greater Geneva Bern area

KBI Biopharma and Selexis SA announces J.D. Mowery as CEO - World Business Outlook

KBI Biopharma and Selexis SA announces J.D. Mowery as CEO World Business Outlook

JSR Life Sciences Consolidates KBI Biopharma and Selexis SA - Contract Pharma

JSR Life Sciences Consolidates KBI Biopharma and Selexis SA Contract Pharma

JSR to acquire Swiss cell line developer Selexis for fusion with KBI - Fierce Biotech

JSR to acquire Swiss cell line developer Selexis for fusion with KBI Fierce Biotech

JSR snaps up cell line developer - BioPharma Dive

JSR snaps up cell line developer BioPharma Dive

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis With KBI Biopharma, Inc. - STT Info

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis With KBI Biopharma, Inc. STT Info

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland - Business Wire

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland Business Wire

Russian approval for non-originator dornase alfa - Generics and Biosimilars Initiative

Russian approval for non-originator dornase alfa Generics and Biosimilars Initiative

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins - BioProcess International

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins BioProcess International

KBI Biopharma and Selexis Appoint Abdelaziz Toumi as Chief Business Officer - Contract Pharma

KBI Biopharma and Selexis Appoint Abdelaziz Toumi as Chief Business Officer Contract Pharma

JSR to Acquire Selexis and Combine Cell Line Specialist with CDMO KBI Biopharma - Genetic Engineering and Biotechnology News

JSR to Acquire Selexis and Combine Cell Line Specialist with CDMO KBI Biopharma Genetic Engineering and Biotechnology News

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product - Business Wire

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product Business Wire

Selexis Appoints Roland Hoffmann- Hecht, PhD, as Chief Business Officer - Business Wire

Selexis Appoints Roland Hoffmann- Hecht, PhD, as Chief Business Officer Business Wire

Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials - Business Wire

Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials Business Wire

Selexis And Generium Launch Omalizumab Biosimilar In Russia - Citeline News & Insights

Selexis And Generium Launch Omalizumab Biosimilar In Russia Citeline News & Insights

Finding Balance in Cell-Line Development - Genetic Engineering and Biotechnology News

Finding Balance in Cell-Line Development Genetic Engineering and Biotechnology News

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant